- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Health Insurers Seek Sharp Rate Increases in 2016
Newly insured consumers under the Affordable Care Act have turned out to be sicker than initially estimated, according to health insurance companies, who are seeking rate increases of at least 20% to 40%, reported the New York Times.
Newly insured consumers under the Affordable Care Act have turned out to be sicker than initially estimated, according to health insurance companies, who are seeking rate increases of at least 20% to 40%, reported the New York Times.
Blue Cross and Blue Shield plans in Minnesota are seeking rate increases that average as much as 54%, according to documents from the federal government and state insurance companies. However, it is important to note that whether these rate increases will hold up on review is far from certain and they could change.
In Oregon, the rate increases for 2016 will be bigger than they have been for years, which will affect consumers profoundly, according to the Oregon State Public Interest Research Group.
Read more at New York Times: http://nyti.ms/1gic5gs
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
